Literature DB >> 12227722

Elevated serum concentration of cardiotoxic lipid peroxidation products in chronic renal failure in relation to severity of renal anemia.

W Siems1, F Carluccio, T Grune, M Jakstadt, S Quast, H Hampl, O Sommerburg.   

Abstract

Patients with end-stage renal disease undergoing hemodialysis (HD) are exposed to oxidative stress. Increased levels of malondialdehyde (MDA) and 4-hydroxylnonenal (HNE) were found in plasma of uremic patients indicating accelerated lipid peroxidation (LPO) as a consequence of multiple pathogenetic factors. The catabolism and action of those products was already intensively studied. As highly reactive metabolites they are able to bind to proteins, nucleic acids, and other molecules. Doing so, they exert molecular signal effects in cells and are able to exacerbate tissue and organ damage, e.g. cardiotoxic effects. Since renal anemia was shown to promote oxidative stress as well, the aim of our investigation was to examine its role in HD patients. Therefore, two groups of HD patients were investigated (group I Hb < 10 g/dl, group II Hb > 10 g/dl) and serum concentrations of MDA, HNE, and of protein carbonyls, a marker for protein oxidation, were determined. All HD patients had significantly higher levels of the LPO products MDA and HNE compared with controls. However, group I patients showed higher MDA and HNE concentrations compared to group II patients. The same result could be seen for protein carbonyls. During HD concentration of both LPO products decreased. However, this was not the case for protein carbonyls. These results lead to the conclusion that optimized correction of the renal anemia may result in a significant reduction of oxidative stress and therefore in the reduction of organ tissue damage. In this way correction of renal anemia will reduce the cardiovascular risk and comorbidity of HD patients improving their prognosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12227722

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  6 in total

Review 1.  Cardiorenal disease: a clinical intersection.

Authors:  Vikram Kalra; Sandeep Mahajan; Sanjay Kumar Agarwal; Suresh Chander Tiwari
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

2.  Correlations of cardiac function with inflammation, oxidative stress and anemia in patients with uremia.

Authors:  Heping Zhang; Lei Fan; Huawei Liao; Lirong Tu; Jie Zhang; Dan Xu; Jiangchao Feng
Journal:  Exp Ther Med       Date:  2021-01-22       Impact factor: 2.447

Review 3.  Physiological Mechanisms of Hypertension and Cardiovascular Disease in End-Stage Kidney Disease.

Authors:  John S Clemmer; Tariq Shafi; Yoshitsugu Obi
Journal:  Curr Hypertens Rep       Date:  2022-06-16       Impact factor: 4.592

4.  Activation of proinflammatory signaling by 4-hydroxynonenal-Src adducts in aged kidneys.

Authors:  Eun Ji Jang; Dae Hyun Kim; Bonggi Lee; Eun Kyeong Lee; Ki Wung Chung; Kyoung Mi Moon; Min Jo Kim; Hye Jin An; Ji Won Jeong; Ye Ra Kim; Byung Pal Yu; Hae Young Chung
Journal:  Oncotarget       Date:  2016-08-09

5.  Serum Concentrations of F2-Isoprostanes and 4-Hydroxynonenal in Hemodialysis Patients in Relation to Inflammation and Renal Anemia.

Authors:  Ingrid Wiswedel; Daniela Peter; Andreas Gardemann; Francesco Carluccio; Hannelore Hampl; Werner Siems
Journal:  Biomark Insights       Date:  2008-05-27

6.  A randomized controlled trial evaluating the erythropoiesis stimulating agent sparing potential of a vitamin E-bonded polysulfone dialysis membrane.

Authors:  Simon W Lines; Angela M Carter; Emma J Dunn; Elizabeth J Lindley; James E Tattersall; Mark J Wright
Journal:  Nephrol Dial Transplant       Date:  2013-11-28       Impact factor: 5.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.